ApoB Test Prevents More Heart Attacks Than LDL, Study Finds
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Northwestern Medicine study published in JAMA found that using apoB to guide cholesterol treatment prevents more heart attacks and strokes than LDL or non-HDL cholesterol testing, while remaining cost-effective for U.S. healthcare payers
- Lead author Ciaran Kohli-Lynch, assistant professor of preventive medicine at Northwestern University Feinberg School of Medicine, said this is the first comprehensive analysis showing apoB-guided treatment intensification offers good value
- ApoB measures the total number of harmful cholesterol-carrying particles in the blood, making it a more direct indicator of cardiovascular risk than LDL or non-HDL levels, which only capture cholesterol content
- The computer simulation modeled 250,000 U.S. adults eligible for statin therapy without existing cardiovascular disease, comparing LDL (<100 mg/dL), non-HDL (<118 mg/dL), and apoB (<78.7 mg/dL) targets with treatment escalated via stronger statins then ezetimibe
- ApoB-guided treatment consistently outperformed both alternatives on lifetime heart attacks, strokes, life expectancy, and quality of life across the simulated cohort
- Updated American Heart Association guidelines issued earlier this year with 10 other medical organizations now recommend cholesterol-lowering therapy at younger ages, making accurate risk stratification more important than ever
- Northwestern coauthors Drs. John Wilkins and Samuel Luebbe contributed to the study, titled "Cost-Effectiveness of ApoB, Non-HDL-C, and LDL-C Goals for Primary Prevention Lipid-Lowering Therapy," supported by an AHA Career Development Award
Why it matters: Heart disease remains the leading U.S. cause of death, and with new guidelines pushing therapy to younger patients, clinicians and payers now have first-of-its-kind cost-effectiveness evidence favoring apoB — but adoption hinges on ordering an extra blood draw beyond the standard lipid panel.
